{
  "schemaVersion": 1,
  "organisationId": "O-f55e57c833a44fafb7c4a9422b9082ce",
  "slug": "axsome-therapeutics-inc",
  "name": "Axsome Therapeutics, Inc.",
  "updatedAt": "2026-10-02T14:03:51.018267Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system conditions, including psychiatric and neurological disorders. The company describes its mission as developing therapies that meaningfully improve patients’ lives and expand treatment options for physicians. [P155389317][P155389652][https://www.axsome.com/about-axsome/]\n\nIts commercial portfolio includes AUVELITY for major depressive disorder and Alzheimer’s disease agitation, SUNOSI for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, and SYMBRAVO for acute migraine treatment. [P155389319][P155389318][P155389320] Axsome’s commercial business is centered in the United States; SUNOSI also has approvals and licensing arrangements covering selected markets outside the U.S. [P155389658][P155389587][P155389598] The company reported $409.6 million in revenue for the six months ended June 30, 2026. [T17919954]\n[P155389317][P155389652][https://www.axsome.com/about-axsome/][P155389319][P155389318][P155389320][P155389658][P155389587][P155389598][T17919954][https://www.axsome.com/about-axsome/]",
      "updatedAt": "2026-10-02T14:03:51.018267Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Axsome’s marketed products are AUVELITY (dextromethorphan/bupropion), an oral treatment for major depressive disorder in adults and agitation associated with Alzheimer’s disease dementia. It is described as an NMDA-receptor antagonist using a proprietary formulation and metabolic-inhibition technology. SUNOSI (solriamfetol) is an oral treatment for excessive daytime sleepiness in adults with obstructive sleep apnea or narcolepsy; it is described as a dopamine and norepinephrine reuptake inhibitor with TAAR1 and 5-HT1A agonist activity. SYMBRAVO (MoSEIC meloxicam/rizatriptan) is an oral acute treatment for migraine with or without aura in adults, combining a selective COX-2 inhibitor with a 5-HT1B/1D agonist. [P155389319][P155389656][P155389318][P155389320]\n\nThe 2026 Q2 report lists investigational programs including solriamfetol for ADHD, binge-eating disorder, MDD with excessive daytime sleepiness and shift-work-disorder sleepiness; AXS-12 (reboxetine) for narcolepsy; AXS-14 (esreboxetine) for fibromyalgia; AXS-05 for smoking cessation; and AXS-20 (balipodect), a PDE10A inhibitor being evaluated for schizophrenia and Tourette syndrome. [P155389666][P155389667][P155389668][P155389665][P155389670] Axsome sells its U.S. products through wholesale distributors, sells SUNOSI in Canada, and licenses SUNOSI for marketing in certain territories outside the U.S. and Canada. [P155389351][P155389587]\n\nFor the six months ended June 30, 2026, product sales represented approximately 99.1% of total revenue: AUVELITY contributed about 81.3%, SUNOSI 16.2%, and SYMBRAVO 1.5%. These shares are calculated from the reported product-sales amounts and total revenue. [T17919954]\n[P155389319][P155389656][P155389318][P155389320][P155389666][P155389667][P155389668][P155389665][P155389670][P155389351][P155389587][T17919954][T17919954][T17919954][T17919954]",
      "updatedAt": "2026-10-02T14:03:51.018267Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Axsome Therapeutics’ principal executive and corporate offices are in New York City, at One World Trade Center. Its disclosed commercial sales include sales to U.S. distributors and Canadian distributors; it also supplies SUNOSI to Pharmanovia for resale in certain markets outside the United States. [P155389351][P155389587][P155389222][P44055615]\n\nPharmanovia holds SUNOSI commercialization and further-development rights in Europe and certain countries in the Middle East and North Africa, and is responsible for clinical development and commercialization in those territories; Axsome manufactures and supplies the product, though the reviewed filing does not specify manufacturing locations. SUNOSI rights in 12 Asian markets, including China, South Korea, and Japan, are held by SK Biopharmaceuticals. The reviewed filing does not provide revenue by country or region, geographic revenue percentages, or employee distribution by location. [P155389598][P155389658][P155389590]\n[P155389351][P155389587][P155389222][P44055615][P155389598][P155389658][P155389590][https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20260630.htm][https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm]",
      "updatedAt": "2026-10-02T14:03:51.018267Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Axsome Therapeutics reports one operating and reportable segment: developing and delivering therapies for central nervous system disorders. Management reviews and allocates resources on a consolidated basis, rather than by product or therapeutic area; accordingly, the single reported segment represents 100% of the company’s reported revenue. [P155389632]\n\nThe company discloses product revenue, not separate reportable segments. Its marketed products address major depressive disorder and Alzheimer’s-disease-associated agitation (AUVELITY), excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy (SUNOSI), and acute migraine (SYMBRAVO). [P155389319][P155389318][P155389320] As an indication of commercial mix—not segment contributions—FY2025 revenue was approximately 79% AUVELITY, 19% SUNOSI product sales, and 1% SYMBRAVO, with the remainder from SUNOSI milestone and royalty revenue. For the six months ended June 30, 2026, the approximate mix was 81% AUVELITY, 16% SUNOSI product sales, 1.5% SYMBRAVO, and 0.9% combined milestone and royalty revenue. [T8507915][T17919954]\n[P155389632][P155389319][P155389318][P155389320][T8507915][T17919954][https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm][https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm]",
      "updatedAt": "2026-10-02T14:03:51.018267Z"
    },
    {
      "type": "HISTORY",
      "text": "Axsome Therapeutics was incorporated in January 2012 by Herriot Tabuteau, M.D., who has led the company since its founding. Its early development portfolio included AXS-02 and AXS-05; the company went public in November 2015, raising approximately $51 million in its IPO. [P190884245][P190884610][P190884244][P190884218]\n\nIn 2022, Axsome moved into commercial operations: the FDA approved Auvelity (then AXS-05) for major depressive disorder, and the company launched it in the United States. That year, Axsome also acquired U.S. and certain international rights to Sunosi, an existing treatment for excessive daytime sleepiness that had received FDA approval in 2019. [P155389319][P155389318][P155389871] The FDA approved Symbravo for acute migraine treatment in January 2025. In April 2026, Auvelity received FDA approval for agitation associated with dementia due to Alzheimer’s disease, adding a second indication for the product. [P155389871][P155389710][P155389319]\n[P190884245][P190884610][P190884244][P190884218][P155389319][P155389318][P155389871][P155389710]",
      "updatedAt": "2026-10-02T14:03:51.018267Z"
    }
  ],
  "sources": [
    {
      "id": "P155389317",
      "href": "https://app.finbar.com/go?id=P155389317",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389652",
      "href": "https://app.finbar.com/go?id=P155389652",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "https://www.axsome.com/about-axsome/",
      "href": "https://www.axsome.com/about-axsome/",
      "label": "www.axsome.com"
    },
    {
      "id": "P155389319",
      "href": "https://app.finbar.com/go?id=P155389319",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389318",
      "href": "https://app.finbar.com/go?id=P155389318",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389320",
      "href": "https://app.finbar.com/go?id=P155389320",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389658",
      "href": "https://app.finbar.com/go?id=P155389658",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389587",
      "href": "https://app.finbar.com/go?id=P155389587",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389598",
      "href": "https://app.finbar.com/go?id=P155389598",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "T17919954",
      "href": "https://app.finbar.com/go?id=T17919954",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389656",
      "href": "https://app.finbar.com/go?id=P155389656",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389666",
      "href": "https://app.finbar.com/go?id=P155389666",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389667",
      "href": "https://app.finbar.com/go?id=P155389667",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389668",
      "href": "https://app.finbar.com/go?id=P155389668",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389665",
      "href": "https://app.finbar.com/go?id=P155389665",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389670",
      "href": "https://app.finbar.com/go?id=P155389670",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389351",
      "href": "https://app.finbar.com/go?id=P155389351",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389222",
      "href": "https://app.finbar.com/go?id=P155389222",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P44055615",
      "href": "https://app.finbar.com/go?id=P44055615",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2025 Y)",
      "documentId": "D-68235526b5e4460b8e1c8dc65224ce39"
    },
    {
      "id": "P155389590",
      "href": "https://app.finbar.com/go?id=P155389590",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20260630.htm",
      "href": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20260630.htm",
      "label": "www.sec.gov"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm",
      "href": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm",
      "label": "www.sec.gov"
    },
    {
      "id": "P155389632",
      "href": "https://app.finbar.com/go?id=P155389632",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "T8507915",
      "href": "https://app.finbar.com/go?id=T8507915",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2025 Y)",
      "documentId": "D-68235526b5e4460b8e1c8dc65224ce39"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm",
      "href": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm",
      "label": "www.sec.gov"
    },
    {
      "id": "P190884245",
      "href": "https://app.finbar.com/go?id=P190884245",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2015 Y)",
      "documentId": "D-bfb970f2665e4506928a7227c5d1bfc6"
    },
    {
      "id": "P190884610",
      "href": "https://app.finbar.com/go?id=P190884610",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2015 Y)",
      "documentId": "D-bfb970f2665e4506928a7227c5d1bfc6"
    },
    {
      "id": "P190884244",
      "href": "https://app.finbar.com/go?id=P190884244",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2015 Y)",
      "documentId": "D-bfb970f2665e4506928a7227c5d1bfc6"
    },
    {
      "id": "P190884218",
      "href": "https://app.finbar.com/go?id=P190884218",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2015 Y)",
      "documentId": "D-bfb970f2665e4506928a7227c5d1bfc6"
    },
    {
      "id": "P155389871",
      "href": "https://app.finbar.com/go?id=P155389871",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    },
    {
      "id": "P155389710",
      "href": "https://app.finbar.com/go?id=P155389710",
      "label": "Axsome Therapeutics, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d4efe10457fe4a2c928807e0680bea9c"
    }
  ]
}